1. Home
  2. CHWY vs PCVX Comparison

CHWY vs PCVX Comparison

Compare CHWY & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chewy Inc.

CHWY

Chewy Inc.

HOLD

Current Price

$26.00

Market Cap

11.0B

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$59.35

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHWY
PCVX
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
9.0B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
CHWY
PCVX
Price
$26.00
$59.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
24
4
Target Price
$43.52
$88.25
AVG Volume (30 Days)
7.2M
1.1M
Earning Date
06-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.52
N/A
Revenue
$12,601,500,000.00
N/A
Revenue This Year
$10.70
N/A
Revenue Next Year
$7.84
N/A
P/E Ratio
$49.56
N/A
Revenue Growth
6.24
N/A
52 Week Low
$22.74
$28.09
52 Week High
$48.62
$65.00

Technical Indicators

Market Signals
Indicator
CHWY
PCVX
Relative Strength Index (RSI) 47.55 49.66
Support Level $24.75 $52.04
Resistance Level $27.77 $64.16
Average True Range (ATR) 1.15 2.20
MACD -0.02 -0.21
Stochastic Oscillator 27.67 17.50

Price Performance

Historical Comparison
CHWY
PCVX

About CHWY Chewy Inc.

Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: